Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NCT05050084 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

2050

Enrollment

OTHER

Sponsor class

Conditions

Prostate Adenocarcinoma

Interventions

DRUG: Bicalutamide
DRUG: Buserelin
DRUG: Darolutamide
DRUG: Degarelix
DRUG: Flutamide
DRUG: Goserelin
DRUG: Histrelin
DRUG: Leuprolide
RADIATION: Radiation Therapy
DRUG: Relugolix
DRUG: Triptorelin

Sponsor

NRG Oncology

Collaborators

[object Object]